Skip to main content

Table 5 Univariable analysis of risk factors for newly developed VTE of 12 patients in three-month observation period

From: Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

Variable No. of patients % per three months OR (95% CI) P
Sex and age (yr.)
 < 70 7 /64 11 1.0 (ref.)  
 ≥ 70 male 1 /19 5 0.5 (0.05–3.9) 0.67
 ≥ 70 female 4 /14 29 3.3 (0.80–13.2) 0.10
BMI
 < 25 6 /74 8 1.0 (ref.)  
 ≥ 25 6 /23 26 4.0 (1.2–14.0)a 0.030*
Reduced mobilityb
 No 11 /87 13 1.0 (ref.)  
 Yes 1 /10 10 0.8 (0.1–6.7) 1.00
Previous chemotherapy
 No 9 /78 12 1.0 (ref.)  
 Yes 3 /19 16 1.4 (0.4–5.9) 0.70
Time from cancer onset (mo.)
 < 6 or >12 7 /85 8 1.0 (ref.)  
 6–12 5 /12 42 8.0 (2.0–31.8)a 0.006*
Central venous access device
 No 0 /7 0 1.0 (ref.)  
 Yes 12 /90 13 2.4 (0.1–44.5) 0.59
Using anti-VEGF antibody
 No 11 /80 14 1.0 (ref.)  
 Yes 1 /17 6 0.4 (0.1–3.3) 0.69
Distant metastases
 No 3 /32 9 1.0 (ref.)  
 Yes 9 /65 14 1.6 (0.4–6.2) 0.75
Developing acute infectionc
 No 24 /67 56 1.0 (ref.)  
 Yes 5 /30 20 0.4 (0.1–1.1) 0.10
Platelet count (/μL)d
 < 350,000 12 /87 12 1.0 (ref.)  
 ≥ 350,000 0 /10 0 0.3 (0.0–5.2) 0.60
Hemoglobin (g/dL)d
 ≥ 10 10 /84 12 1.0 (ref.)  
 < 10 2 /13 15 1.4 (0.3–7.0) 0.66
Leukocyte count (/μL)d
 < 11,000 12 /93 13 1.0 (ref.)  
 ≥11,000 0 /4 0 0.7 (0.0–14.3) 1.00
D-dimer (μg/mL)d, e
 <1.5 3 /36 8 1.0 (ref.)  
 ≥1.5 7 /58 12 1.5 (0.4–6.3) 0.74
TAT (ng/mL)d, e
 < 2.1 2 /50 2 1.0 (ref.)  
 ≥ 2.1 8 /44 18 5.3 (1.1–26.6)a 0.042*
PIC (μg/mL)d, e
  ≥ 1.8 0 /21 0 1.0 (ref.)  
  < 1.8 10 /73 14 7.1 (0.4–126.5) 0.11
TAT ≥2.1 ng/mL and PIC <1.8 μg/mLd, e
 No 2 /65 3 1.0 (ref.)  
 Yes 8 /29 28 12.0 (2.4–61.0)a 0.001*
  1. Abbreviations and footnotes are as in Table 2.